Tobin Schilke - 23 Feb 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Financial Officer
Signature
/s/ Tobin Schilke
Issuer symbol
CRNX
Transactions as of
23 Feb 2026
Net transactions value
$0
Form type
4
Filing time
25 Feb 2026, 16:36:22 UTC
Previous filing
11 Mar 2025
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schilke Tobin Chief Financial Officer C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke 25 Feb 2026 0001678984

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +32,000 +61% $0.000000 84,834 23 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 23 Feb 2026 Common Stock 50,000 $43.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
F2 Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
F3 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.